Prelude Therapeutics (PRLD) Current Assets (2019 - 2026)
Prelude Therapeutics (PRLD) posted Current Assets of $84.6 million for Q1 2026, down 19.96% sequentially from $105.7 million in Q4 2025, and down 17.39% YoY from $102.4 million in Q1 2025.
Prelude Therapeutics (PRLD) Current Assets (2019 - 2026) Analysis & Trends
Prelude Therapeutics has reported Current Assets for 8 years, with the latest figure at $84.6 million in Q1 2026.
- Quarterly Current Assets fell 17.39% year-over-year to $84.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84.6 million (down 17.39% YoY) and the FY2025 annual result came in at $105.7 million, down 22.23% from the prior year.
- Current Assets retreated to $84.6 million in Q1 2026 per PRLD's latest filing, from $105.7 million in the prior quarter.
- Over five years, Current Assets peaked at $270.0 million in Q1 2022 and troughed at $58.3 million in Q3 2025.
- A 5-year average of $174.4 million and a median of $182.7 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2024 and 2025: Current Assets climbed 17.18% in 2024, then plunged 62.7% in 2025.
- Over 5 years, Current Assets stood at $204.4 million in 2022, then rose by 15.27% to $235.6 million in 2023, then slumped by 42.32% to $135.9 million in 2024, then decreased by 22.23% to $105.7 million in 2025, then retreated by 19.96% to $84.6 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $84.6 million, $105.7 million, and $58.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | 154.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 154.90 Mn |
| Mar 31, 2026 | 84.59 Mn |
| Dec 31, 2025 | 105.69 Mn |
| Sep 30, 2025 | 58.33 Mn |
| Jun 30, 2025 | 76.88 Mn |
| Mar 31, 2025 | 102.40 Mn |
| Dec 31, 2024 | 135.90 Mn |
| Sep 30, 2024 | 156.39 Mn |
| Jun 30, 2024 | 182.71 Mn |
| Mar 31, 2024 | 205.37 Mn |
| Dec 31, 2023 | 235.59 Mn |
| Sep 30, 2023 | 234.92 Mn |
| Jun 30, 2023 | 260.21 Mn |
| Mar 31, 2023 | 175.26 Mn |
| Dec 31, 2022 | 204.38 Mn |
| Sep 30, 2022 | 226.89 Mn |
| Jun 30, 2022 | 248.62 Mn |
| Mar 31, 2022 | 269.97 Mn |
| Dec 31, 2021 | 295.12 Mn |
| Sep 30, 2021 | 325.90 Mn |